AJMC February 11, 2022
Bruce Feinberg, DO, Mark G. Kris, MD, Kenna R. Mills Shaw, PhD, Eugean Jiwanmall, MPH, MBA
The rationale for migrating away from single, spot testing to comprehensive genomic profiling assays in oncology.
Bruce Feinberg, DO: I keep stepping back, taking the one step back because I don’t want to lose our audience. But for most of the audience, they probably are more familiar with NGS [next-generation sequencing] than they are with CGP [comprehensive genomic profiling]. But NGS is the method and CGP is the outcome of that method, if I might think of it that way. But if you could go into it, into a little bit more depth and distinguish between what we were doing in terms of a single test, and looking for potentially a protein vs the gene....
Related Articles: